Omeros Corporation $OMER Shares Bought by Corient Private Wealth LLC

Corient Private Wealth LLC boosted its holdings in shares of Omeros Corporation (NASDAQ:OMER) by 13.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 688,025 shares of the biopharmaceutical company’s stock after purchasing an additional 79,263 shares during the quarter. Corient Private Wealth LLC owned approximately 0.97% of Omeros worth $11,817,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. UBS Group AG raised its stake in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after buying an additional 1,513,893 shares during the period. JPMorgan Chase & Co. grew its stake in Omeros by 1,201.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after acquiring an additional 384,168 shares during the period. AlphaQuest LLC grew its stake in Omeros by 8,259,600.0% in the 4th quarter. AlphaQuest LLC now owns 82,597 shares of the biopharmaceutical company’s stock valued at $1,419,000 after acquiring an additional 82,596 shares during the period. Vanguard Group Inc. increased its holdings in Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after acquiring an additional 666,357 shares in the last quarter. Finally, AXQ Capital LP purchased a new stake in Omeros in the 4th quarter worth $501,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on OMER. Wall Street Zen downgraded shares of Omeros from a “buy” rating to a “hold” rating in a report on Sunday, June 7th. Zacks Research raised shares of Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Omeros in a research note on Wednesday, June 10th. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Tuesday, April 21st. Finally, Weiss Ratings lowered Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $40.33.

Insider Buying and Selling at Omeros

In other news, Director Thomas J. Cable sold 7,500 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the completion of the sale, the director owned 35,067 shares of the company’s stock, valued at $407,127.87. This represents a 17.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is currently owned by company insiders.

Omeros Stock Up 1.5%

NASDAQ OMER opened at $10.48 on Wednesday. Omeros Corporation has a 52 week low of $2.95 and a 52 week high of $17.65. The business’s fifty day simple moving average is $12.01 and its 200-day simple moving average is $11.89. The firm has a market cap of $758.54 million, a PE ratio of 14.97 and a beta of 2.52.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.16. The firm had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $4.19 million. Research analysts expect that Omeros Corporation will post -0.94 EPS for the current year.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.